[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"indigestion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:indigestion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,76,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100352163","phase-2-effects-of-ondansetron-on-gastrointestinal-sensorimotor-dysfunctions-in-diabetes-mellitus-and-dyspepsia-100352163",false,"NCT03865290","Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia","Inclusion Criteria:\n\n* Healthy male or non-pregnant, non-breastfeeding female volunteers;\n* 18-75 years old;\n* Able to provide written informed consent before participating in the study\n* Able to communicate adequately with the investigator and to comply with the requirements for the entire study; including the willingness and ability to consume the components of the test meals\n* Symptoms of dyspepsia (i.e., early satiety, postprandial discomfort, nausea, vomiting, regurgitation)\n* Patients in the DM group will also require Type 1 or 2 DM of ≥ 3 years duration; in patients with type 2 DM, the dyspepsia symptoms should have begun or worsened after DM was diagnosed\n\nExclusion Criteria:\n\n* Major abdominal surgery (i.e., appendectomy, cholecystectomy, tubal ligation, hysterectomy, herniorrhaphy, and limited colonic resection are permissible)\n* Clinical evidence (including physical exam and EKG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and\u002For pose safety concerns\n* Current use of opiates, alpha adrenergic agonists, metoclopramide, monoamine oxidase inhibitors, more than one serotonergic medication, and high doses of anticholinergic agents (eg, amitriptyline greater than 50 mg daily). If medically safe, these drugs may be discontinued for four half lives prior to study assessments.\n* Treatment with GLP-1 agonists and amlyin which cause vagal blockade and may affect central processing of pain\n* Bleeding or clotting disorders or medications that increase risk of bleeding from mucosal biopsies\n* Positive tissue transglutaminase antibodies (TTG),\n* Pregnant or breast-feeding females\n* Known intolerance or allergy to eggs\n* Poor peripheral venous access, if central venous access is not available\n* Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study\n* History of Long QT Syndrome or prolonged QT interval (i.e., corrected QT interval \\> 480 ms)\n* Current symptoms of a functional gastrointestinal disorder assessed by questionnaire\n* Severe vomiting that would preclude tube placement or participation in the study\n* Structural cause for symptoms by endoscopy within the past 12 months\n* Patients with gastric pacemakers",true,"ALL","18 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondansetron will also be studied to determine its effects on gastrointestinal function and associated symptoms.",[27,28],"Indigestion","Diabetes Mellitus","RECRUITING","2026-04-28",{"date":32,"type":33},"2026-05-04","ACTUAL",{"date":35,"type":33},"2019-04-02",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"Mayo Clinic","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":41},"100574160","a-prospective-multicentre-real-world-assessment-of-the-efficacy-of-danning-tablets-in-alleviating-digestive-symptoms-100574160","NCT06755671","A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms","Inclusion Criteria:\n\n* Patients between 18 and 75 years old\n* Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation\n* Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia\n* Patients agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Past history or comorbidity of malignant tumor\n* Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases\n* Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)\n* Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician\n* Pregnancy or breastfeeding\n* Participation in other clinical trials within the past 3 months\n* Other circumstances determined as ineligible by the research physician",{"count":49,"type":21},4500,"OBSERVATIONAL","The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.\n\nThe main questions it aims to answer are:\n\nHow effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?\n\nParticipants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.",[27,53,54,55,56,57,58,59],"Dyspepsia","Bloating","Loss of Appetite","Reflux Acid","Constipation","Upper Abdominal Pain","Functional Dyspepsia",[61,62,63,64,65],"Danning Tablets","dyspepsia","indigestion","observational study","real world study","2025-05-13",{"date":68,"type":33},"2025-05-14",{"date":70,"type":33},"2025-04-30",{"date":72,"type":21},"2027-06-30",{"name":74,"class":75},"Shanghai Hutchison Pharmaceuticals Limited","INDUSTRY",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":15,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100559809","clinical-study-of-de-stress--happy-gut-powder-for-stress-and-indigestion-in-adults-100559809","NCT06568965","Clinical Study of De-Stress & Happy Gut Powder for Stress and Indigestion in Adults.","A Randomized, Double-blind, Placebo-controlled, Parallel Arm Clinical Trial of De-Stress and Happy Gut Powder in Relieving Stress and Functional Dyspepsia Symptoms in Adults.","Inclusion Criteria:\n\n1. Male and female participants aged 21-50 years both inclusive\n2. Suffering from self-reported mild to moderate stress on the PSS scale score less than or equal to 26\n3. Participants willing to participate in clinical trials and who have read understood and signed the informed consent form\n4. No severe anxiety and depression i.e. Generalized anxiety disorder GAD score less than or equal to 10 and Patients' health questionnaire-9 PHQ-9 score less than or equal to 14\n5. Diagnosis of functional dyspepsia\u002Fnon-ulcer dyspepsia by fulfilling Rome-III criteria\n6. Participant should be suffering with at least 4 or more symptoms mentioned below and with a total symptom score of 20 or more based on a 7-point Likert scale (a) Upper abdominal fullness (b) Upper abdominal pain (c) Belching (d) Bloating (e) Early satiety (f) Nausea (g) Vomiting (h) Regurgitation (i) Heartburn (j) Loss of appetite\n\nExclusion Criteria:\n\n1. Inability to perform any of the assessments required for endpoint analysis\n2. Known hypersensitivity to investigational products\n3. Participants with a history of substance abuse, drugs, heavy use of alcohol, and\u002For smoking within last 5 years\n4. Advanced chronic illness that would impair follow-up or monitoring\n5. Participants who have used dietary supplements, medications, such as oral\u002FIV antibiotics or probiotics, or supplements known to affect hunger, satiety, appetite, or gut microbiome within three months prior to recruitment. Additionally, individuals currently using nutraceuticals, allopathic, or ayurvedic supplements for stress and or gastrointestinal health management;\n6. Participants suffering from abdominal obesity that is waist circumference of more than 80 cm in females and of more than 90 cm in male;\n7. Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study\n8. Participants with current or past diagnoses of peptic ulcer disease, gastroesophageal reflux disorder (GERD), or irritable bowel syndrome (IBS), as well as those who have undergone surgery related to these conditions\n9. Have any other neurodegenerative diseases, mental illness or dementia\n10. Any other clinical condition in the judgment of investigator finds the study participation unsuitable for the participant.","21 Years","50 Years",{"count":86,"type":21},81,[88],"NA","The current study focuses on clinical validation of efficacy of nutraceutical product in relieving stress and functional dyspepsia symptoms in adults for gut health. The effect of these nutraceuticals not only targets the physical symptoms but also enhances overall well-being. Improved digestive health leads to better nutrient absorption, which is essential for energy levels and immune function. Reduced stress levels contribute to better sleep quality, cognitive function, and emotional stability.",[91,53,27],"Stress",[93,53,27],"stress","NOT_YET_RECRUITING","2024-08-22",{"date":97,"type":33},"2024-08-23",{"date":99,"type":21},"2024-09-05",{"date":101,"type":21},"2024-12-28",{"name":103,"class":75},"Herbolab India Pvt. Ltd.",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100550891","the-impact-and-effect-of-traditional-chinese-medicine-treatment-on-organ-failure-in-critically-ill-patients-100550891","NCT06452966","The Impact and Effect of Traditional Chinese Medicine Treatment on Organ Failure in Critically Ill Patients","Inclusion Criteria:\n\n* Age 20 and above\n* Surgical ICU patients\n* The use of Chinese medicine must be approved by the attending physician in the surgical intensive care unit\n\nExclusion criteria:\n\n* Patients' family members refuse TCM intervention","20 Years",{"count":112,"type":21},350,[88],"Critically ill patients are at risk of or suffering from one or more key organs or organ system failure. This study will measure the effect of traditional Chinese medicine(TCM) interventions on critically ill patients admitted to the intensive care unit (ICU).\n\nThe goal of this clinical trial is to learn if traditional Chinese medicine(TCM) is effective for prevention and treatment of organ failure in ICU patients. Patients in this group will receive intervention for 2 weeks.\n\nA multi-center non-randomized real word data study, will include 3 groups: intervention group (TCM)(n=70), control group and historical control group (admitted to the same ICU in the period of 01.2019 to 12.2023).\n\nMain outcomes include sequential organ failure assessment (SOFA) score, ICU length of stay, hospital length of stay, number of days of respirator uses and western medicine medication used study follow up will be 2 weeks.",[116,27,117,118,119],"Organ Failure, Multiple","Delayed Gastric Emptying","Respiratory Failure","Morality",[121,122,123,124],"acupuncture","chinese medicine","Organ Failure","intensive care","2024-06-06",{"date":127,"type":33},"2024-06-11",{"date":129,"type":33},"2024-05-07",{"date":131,"type":21},"2027-05-30",{"name":133,"class":40},"China Medical University Hospital"]